Drug Type Mesenchymal stem cell therapy |
Synonyms bone marrow-derived mesenchymal stromal cells(The University of Queensland), Bone-marrow derived MSCs(The University of Queensland) |
Target- |
Mechanism Cell replacements |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Depressive Disorder | Phase 3 | US | 28 Mar 2019 | |
Genetic Diseases, Inborn | Phase 3 | US | 28 Mar 2019 | |
Inflammation | Phase 3 | US | 28 Mar 2019 | |
Osteoarthritis, Knee | Phase 3 | US | 28 Mar 2019 | |
Pain | Phase 3 | US | 28 Mar 2019 | |
Lung transplant rejection | Phase 2 | AU | 31 Mar 2020 | |
Allograft Rejection | Phase 2 | AU | 21 Apr 2017 | |
Fibrosis | Phase 2 | NL | 31 Mar 2014 | |
Kidney Failure, Chronic | Phase 2 | NL | 31 Mar 2014 | |
Opportunistic Infections | Phase 2 | NL | 31 Mar 2014 |
Phase 3 | 475 | (Bone Marrow Derived MSCs) | cmxqadnher(tbyrkpuove) = rgxmdrhcrw maditqpowo (tjbxdtdupk, kneitraymb - enustanxid) View more | - | 27 Jul 2023 | ||
Adipose-derived MSCs (Adipose-derived MSCs) | cmxqadnher(tbyrkpuove) = esojxsokaw maditqpowo (tjbxdtdupk, kyfixtceqc - ddadcwywqu) View more | ||||||
HOVON-113 (EHA2022) Manual | Phase 3 | 41 | Mesenchymal stromal cell | rfutggopih(eqfkranrjs) = zfpibyoiqy owyfdvhzxj (lzvxxpuxdd ) View more | Negative | 12 May 2022 | |
placebo | rfutggopih(eqfkranrjs) = jprtfudxfv owyfdvhzxj (lzvxxpuxdd ) View more |